Scarica l'app Stockscreener
1.11
11.20%
-0.14
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ALZN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.25
Aprire:
$1.21
Volume 24 ore:
785.90K
Relative Volume:
3.67
Capitalizzazione di mercato:
$6.03M
Reddito:
-
Utile/perdita netta:
$-7.39M
Rapporto P/E:
-6.9375
EPS:
-0.16
Flusso di cassa netto:
$-6.12M
1 W Prestazione:
-6.72%
1M Prestazione:
-15.27%
6M Prestazione:
-72.18%
1 anno Prestazione:
-86.81%
Intervallo 1D:
$1.11
$1.22
Intervallo di 1 settimana:
$1.11
$1.34
Portata 52W:
$1.06
$15.06
Alzamend Neuro Inc Stock (ALZN) Company Profile
Nome
Alzamend Neuro Inc
Settore
Industria
Telefono
844-722-6333
Indirizzo
3500 LENOX RD. NE, ATLANTA
Confronta ALZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.11 | 6.03M | 0 | -7.39M | -6.12M | -10.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-01 | Iniziato | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Borsa (ALZN) Ultime notizie
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo - Business Wire
Alzamend Neuro Reports Strong Financial Results and Clinical Program Updates - Defense World
Alzamend Neuro says net cash gained by financing activity $8.3M - Yahoo Finance
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs - Business Wire
Alzamend Neuro Inc. (ALZN) reports earnings - Quartz
Alzamend Neuro stock hits 52-week low at $1.24 amid market challenges - Investing.com Nigeria
Alzamend reports promising results for brain-targeted lithium therapy - Investing.com India
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice - Business Wire
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential - Yahoo Finance
Alzamend Neuro stock hits 52-week low at $1.39 amid sharp decline - Investing.com
Alzamend Neuro sets trial dosage for AL001 lithium therapy - Alzheimer's News Today
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s - BioSpace
Alzamend Neuro advances Alzheimer's treatment with new lithium dose - Investing.com
Alzamend Neuro advances Alzheimer's treatment with new lithium dose By Investing.com - Investing.com South Africa
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's - Yahoo Finance
Alzamend Neuro Inc (ALZN) receives a Buy rating from Ascendiant Capital Markets - Knox Daily
Alzamend Neuro Inc (ALZN) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Alzamend Neuro Inc (ALZN-Q) QuotePress Release - The Globe and Mail
Alzamend Neuro regains Nasdaq compliance with equity rule By Investing.com - Investing.com UK
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - StockTitan
Alzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42 - MSN
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference - Barchart
Nasdaq Bank Index (BANK) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Alzamend Neuro enters agreement for $6.5 million ATM offering - Investing.com India
Alzamend Neuro enters agreement for $6.5 million ATM offering By Investing.com - Investing.com Australia
Globalfoundries Inc (GFS-Q) QuotePress Release - The Globe and Mail
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session - MSN
A Guide To The Risks Of Investing In Alzamend Neuro Inc (ALZN) - Knox Daily
Alzamend Neuro Inc: Rising -96.02% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Alzamend Neuro stock hits 52-week low at $1.81 amid market challenges - Investing.com
Understanding the Risks of Investing in Alzamend Neuro Inc (ALZN) - Knox Daily
New partners team up for Phase 2 trial of novel lithium therapy AL001 - Alzheimer's News Today
Ratios Reveal: Breaking Down Alzamend Neuro Inc (ALZN)’s Financial Health - The Dwinnex
Keeping an Eye on Alzamend Neuro Inc (ALZN) After Insider Trading Activity - Knox Daily
Alzamend Neuro Inc (ALZN) is a good investment, but the stock may be overvalued - US Post News
Alzamend Neuro Inc [ALZN] Records 50-Day SMA of $3.50 - Knox Daily
It is Poised to be a Bull Market for Alzamend Neuro Inc (ALZN) - SETE News
Investing in Alzamend Neuro Inc (ALZN): What You Must Know - Knox Daily
Market Momentum: Alzamend Neuro Inc (ALZN) Registers a -7.47 Decrease, Closing at 2.85 - The Dwinnex
Alzamend partners with Mass General for clinical trials - Investing.com
Examining Alzamend Neuro Inc (ALZN) more closely is necessary - US Post News
Alzamend partners with Mass General for clinical trials By Investing.com - Investing.com UK
Alzamend Neuro Issues Letter to Stockholders - StockTitan
ALZN Stock Sees Surge of Approximately 72.96% in Last Five Days - Knox Daily
Daily Market Movement: Alzamend Neuro Inc (ALZN) Sees a -0.91 Decrease, Closing at 4.35 - The Dwinnex
Get in on Alzamend Neuro Inc’s (ALZN) buy-in window today! - SETE News
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board - Quantisnow
Alzamend Neuro Inc [ALZN] Stock trading around $5.85 per share: What’s Next? - The DBT News
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher - MSN
Alzamend Neuro Inc Azioni (ALZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alzamend Neuro Inc Azioni (ALZN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Jul 31 '24 |
Buy |
3.74 |
25 |
93 |
77,193 |
| AULT MILTON C III | Director |
Apr 19 '24 |
Buy |
0.69 |
1,000 |
688 |
771,699 |
| AULT MILTON C III | Director |
Apr 01 '24 |
Buy |
0.91 |
334 |
304 |
770,699 |
| AULT MILTON C III | Director |
Jan 05 '24 |
Buy |
1.06 |
2,000 |
2,127 |
770,365 |
| AULT MILTON C III | Director |
Jan 05 '24 |
Buy |
1.02 |
5,000 |
5,092 |
768,365 |
| AULT MILTON C III | 10% Owner |
Dec 26 '23 |
Buy |
0.90 |
500 |
450 |
26,032 |
| AULT MILTON C III | 10% Owner |
Dec 22 '23 |
Buy |
0.92 |
200 |
185 |
166,866 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):